Anti-Human IL-33

Purified Recombinant Human IL-33 (>98%)

This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.4 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.

Lyophilized

The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Immunohistochemistry on Frozen Sections: This antibody should give satisfactory staining results when used on frozen sections at a concentration of 5-15 µg/ml.
Neutralization: This antibody is useful for neutralization of Human IL-33 bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Human IL-33 (at 1 ng/ml) is 0.75-3 µg/ml.

Goat Anti-Human Interleukin 33 (IL-33) recognizes Human IL-33. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

IL-33 is expressed by a wide variety of cell types, including fibroblasts, mast cells, dendritic cells, macrophages, osteoblasts, endothelial cells, and epithelial cells.

IL-33 is a 30 kD proinflammatory cytokine that belongs to the IL-1 superfamily. It signals inflammation in the body via the stimulation of macrophages, neutrophils, B cells, Th2 cells, eosinophils, basophils and mast cells. IL-33 is a ligand for IL33R (ST2), which is part of a cytokine receptor gene cluster that includes IL-1RI and IL-1RII. IL-33 binds ST2 and complexes with the IL-1R Accessory Protein (IL-1R-AcP) to form a functional signaling receptor complex facilitating the activation of NF-B and MAP kinase signaling pathways resulting in the production of type 2 cytokines from polarized Th2 cells. IL-33R can exist as a type I transmembrane glycoprotein or a soluble glycoprotein. The soluble IL-33R is thought to serve as a decoy receptor which competitively antagonizes the binding of IL-33 thereby reducing its biological effects. IL-33 has been linked with asthma, allergies, endometriosis, and hay fever. In addition, IL-33 resides in keratinocytes of the skin and is thought to trigger the itching associated with dermatitis when subjected to irritation or allergic conditions. Furthermore, in APP/PS1 mice, IL-33 has been shown to be effective in reversing the buildup and preventing the new formation of amyloid plaques that are characteristic of Alzheimer’s disease. However, the action of extracellular IL-33 is limited due to rapid oxidation that causes a molecular conformational change which prevents it from binding to the ST2 receptor.